Back to Search
Start Over
ABCL-351: Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL).
- Source :
- Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 1, Vol. 21, pS393-S394, 2p
- Publication Year :
- 2021
Details
- Language :
- English
- ISSN :
- 21522650
- Volume :
- 21
- Database :
- Complementary Index
- Journal :
- Clinical Lymphoma, Myeloma & Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 152099213
- Full Text :
- https://doi.org/10.1016/S2152-2650(21)01892-9